Juniper Pharmaceuticals (JNP) announced that a Phase 2b clinical trial evaluating COL-1077, an investigational 10% lidocaine bioadhesive gel, for the reduction in pain intensity in women undergoing an endometrial biopsy with tenaculum (surgical clamp) placement, failed to meet its primary and secondary endpoints. CEO Alicia Secor said that the company is discontinuing development of COL-1077 based on the results. JNP shares were inactive in pre-market trading.